Breaking News, Collaborations & Alliances

AVEO Earns $5M Biogen Milestone

AVEO Pharmaceuticals, Inc. has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, for the selection of the first humanized antibody development candidate from its ErbB3 program.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AVEO Pharmaceuticals, Inc. has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, for the selection of the first humanized antibody development candidate from its ErbB3 program. In March 2009, AVEO entered an exclusive option and license agreement with Biogen for the development and commercialization of AVEO’s discovery-stage ErbB3-targeted antibodies for the potential treatment and diagnosis of cancer and other diseases. Under terms of t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters